A. Du-cetuximab-et-des-chimiothérapies, .. Vads, and .. , 38 5.2.2.2 Cetuximab et première ligne de chimiothérapie pour la prise en charge des CE VADS métastatiques et, p.40

N. Evaluation-de-la-fonction-des, C. , and C. , 68 3.2.1 Numération formule sanguine (NFS), p.68

.. Limites-d-'étude, Les anticorps humains anti-chimériques (HACA), 99 2.2 Voies alternatives de l'immunité et résistances, p.101

F. Polymorphisme, une meilleure survie pour le traitement curatif par cetuximab ?, p.110

L. Elargissement-de, 112 6.1.2 Utilisation de la base de données de l'étude, p.112

.. Amélioration-thérapeutique, 115 6.3.1 Hypersensibilité et choc anaphylactique, 116 6.3.3 Restituer la fonction des Natural Killer (IL-2, IL-15 et IL-21), p.116

. Annexe, Protocoles de manipulation: « Principe of RecoverAll TM Total Nucleic Acid Isolation Kit Protocol (Ambion ® ) » rédigé lors des manipulations effectuées par moi-même en Juin, 2010.

D. Hanahan and R. Weinberg, The Hallmarks of Cancer, Cell, vol.100, issue.1, pp.57-70, 2000.
DOI : 10.1016/S0092-8674(00)81683-9

R. Zandi, A. Larsen, P. Andersen, M. Stockhausen, and H. Poulsen, Mechanisms for oncogenic activation of the epidermal growth factor receptor, Cellular Signalling, vol.19, issue.10, pp.2013-2023, 2007.
DOI : 10.1016/j.cellsig.2007.06.023

J. Ferlay, H. Shin, F. Bray, D. Forman, C. Mathers et al., Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008, International Journal of Cancer, vol.8, issue.19, 2004.
DOI : 10.1002/ijc.25516

J. Ferlay, D. Parkin, E. Steliarova-foucher, P. Grosclaude, N. Bossard et al., Estimates of cancer incidence and mortality in Europe in 2008, Remontet L and Velten M: Cancer incidence and mortality in France over the period 1980-2005. Rev Epidemiol Sante Publique, pp.765-81, 2008.
DOI : 10.1016/j.ejca.2009.12.014

S. Marur, D. Souza, G. Westra, W. Forastiere, and A. , HPV-associated head and neck cancer: a virus-related cancer epidemic, The Lancet Oncology, vol.11, issue.8, pp.781-789, 2010.
DOI : 10.1016/S1470-2045(10)70017-6

A. Forastiere, W. Koch, and A. Trotti, Head and Neck Cancer, New England Journal of Medicine, vol.345, issue.26, pp.1890-1900, 2001.
DOI : 10.1056/NEJMra001375

R. Herbst, Review of epidermal growth factor receptor biology, International Journal of Radiation Oncology*Biology*Physics, vol.59, issue.2
DOI : 10.1016/j.ijrobp.2003.11.041

L. Coussens and J. Hayflick, Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells The discovery of receptor tyrosine kinases: targets for cancer therapy Epidermal Growth Factor, Radiat. Oncol. Biol. Phys. Nature. Nat. Rev. Cancer. J Biol Chem, vol.309, issue.12, pp.21-27, 1984.

R. Deryncke, G. Plowman, J. Green, M. Donald, V. Neubauer et al., The physiology of transforming growth factor-alpha The amphiréguline gene encodes a novel epidermal growth factorrelated protein with tumor-inhibitory activity, Adv Cancer Res. Mol Cel Biol, vol.58, issue.14, pp.27-52, 1990.

Y. Shing, G. Christofori, D. Hanahan, Y. Ono, R. Sasada et al., Betacellulin: a mitogen from pancreatic beta cell tumors A heparinbinding growth factor secreted by macrophage-like cells that is related to EGF, Science. Science, vol.259, issue.16, pp.1604-1611, 1991.

H. Toyoda, T. Komurasaki, Y. Ikeda, M. Yoshimoto, and S. Morimoto, Molecular cloning of mouse epiregulin, a novel epidermal growth factor-related protein, expressed in the early stage of development, FEBS Lett, vol.377, issue.17, pp.403-410, 1995.

E. Tzahar, ErbB-3 and ErbB-4 function as the respective low and high affinity receptors of all Neu differenciation factor/heregulin isoforms ErbB-2, the prefered heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling, J Biol Chem. EMBO J, vol.269, issue.16, pp.25226-25259, 1994.

P. Hubert, Growth factor of the EGF family and their receptors, Bull Cancer, vol.94, issue.20, pp.137-182, 2007.

J. Jeroen, L. Van-bueren, K. Wim, A. Bleeker, A. Brännström et al., The antibody zalutumumab inhibits epidermal growth factor receptor signaling by limiting intra-and intermolecular flexibility, PNAS, vol.105, issue.21, pp.6109-6123, 2008.

M. Rebucci, Mécanismes de résistance au cetuximab et influence des associations de traitement dans les lignées cellulaires des cancers des voies aérodigestives supérieures, Thèse de Sciences ? Ecole doctorale de l'Université de Lille II, pp.1-229, 2010.

E. Griner and M. Kazanietz, Protein kinase C and other diacylglycerol effectors in cancer, Nature Reviews Cancer, vol.10, issue.4, pp.281-94, 2007.
DOI : 10.1038/nrc2110

J. Koivunen, V. Aaltonen, and J. Peltonen, Protein kinase C (PKC) family in cancer progression, Cancer Letters, vol.235, issue.1, pp.1-10, 2006.
DOI : 10.1016/j.canlet.2005.03.033

J. Engelman, J. Luo, and L. , The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism, Nature Reviews Genetics, vol.61, issue.8, pp.606-625, 2006.
DOI : 10.1073/pnas.84.14.5034

D. Alessi and P. Cohen, Mechanism of activation and function of protein kinase B, Current Opinion in Genetics & Development, vol.8, issue.1, pp.55-62, 1998.
DOI : 10.1016/S0959-437X(98)80062-2

I. Vivanco and C. Sawyers, The phosphatidylinositol 3-Kinase???AKT pathway in human cancer, Nature Reviews Cancer, vol.2, issue.7, pp.489-501, 2002.
DOI : 10.1038/nrc839

A. Batzer, D. Rotin, J. Urena, E. Skolnik, and J. Schlessinger, Hierarchy of binding sites for Grb2 and Shc on the epidermal growth factor receptor., Molecular and Cellular Biology, vol.14, issue.8, pp.5192-201, 1994.
DOI : 10.1128/MCB.14.8.5192

Y. S. Seger and R. , The extracellular signal-regulated kinase: multiple substrates regulate diverse cellular functions, Growth Factors, vol.24, issue.29, pp.21-44, 2006.

J. Robert, Signalisation cellulaire et cancer, 2010.
DOI : 10.1007/978-2-8178-0028-8

A. Lenferink, Differential endocytic routing of homo- and hetero-dimeric ErbB tyrosine kinases confers signaling superiority to receptor heterodimers, The EMBO Journal, vol.17, issue.12, pp.3385-97, 1998.
DOI : 10.1093/emboj/17.12.3385

C. Reddy, A. Wells, and D. Lauffenburger, Receptor-mediated effects on ligand availability influence relative mitogenic potencies of epidermal growth factor and transforming growth factor ??, Journal of Cellular Physiology, vol.266, issue.3, pp.512-534, 1996.
DOI : 10.1002/(SICI)1097-4652(199603)166:3<512::AID-JCP6>3.0.CO;2-S

J. Woodburn, The Epidermal Growth Factor Receptor and Its Inhibition in Cancer Therapy, Pharmacology & Therapeutics, vol.82, issue.2-3, pp.241-50, 1999.
DOI : 10.1016/S0163-7258(98)00045-X

D. Salomon, R. Brandt, F. Ciardello, N. Normanno, D. Shin et al., Epidermal growth factor-related peptides and their receptors in human malignancies, Critical Reviews in Oncology/Hematology, vol.19, issue.3, pp.183-232, 1994.
DOI : 10.1016/1040-8428(94)00144-I

R. Bei, A. Budillon, and L. Masuelli, Frequent overexpression of multiple ErbB receptors by head and neck squamous cell carcinoma contrasts with rare antibody immunity in patients, The Journal of Pathology, vol.157, issue.3, pp.317-342, 2004.
DOI : 10.1002/path.1642

R. , B. De-jong, R. Keuning, J. Hermans, J. Schuuring et al., Protein expression of cancer associated genes: biopsy material compared to resection material in laryngeal cancer EGFR and cancer prognosisPrognostic value of epidermal growth factor receptor], Anal Quant Cytol Histol. Anticancer Res. Eur J Cancer. Bull Cancer, vol.32, issue.40, pp.78-89, 1998.

K. Ang, B. Berkey, and X. Tu, Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma, Cancer Res, vol.62, pp.7350-7356, 2002.

K. Ang, N. Andratschke, and L. Milas, Epidermal growth factor receptor and response of head-and-neck carcinoma to therapy, International Journal of Radiation Oncology*Biology*Physics, vol.58, issue.3, pp.959-65, 2004.
DOI : 10.1016/j.ijrobp.2003.07.010

D. Raben, B. Helfrich, and D. Chan, The effects of cetuximab alone and in combination with radiation and/or chemotherapy in lung cancer The tyrosine kinase inhibitor ZD1839 ( " Irissa " ) inhibits HER2-driven signaling and suppresses the growth of HER2- overexpressing tumor cells, Clin Cancer Res. Cancer Res, vol.11, issue.61, pp.795-805, 2001.

N. Goldstein, M. Prewett, K. Zuklys, P. Rockwell, and J. Mendelsohn, Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model, Clin Cancer Res, vol.1, pp.1311-1319, 1995.

D. Souza, J. Davis, D. Zhang, Y. Khattri, A. Seiwert et al., A Phase II Study of Lapatinib in Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck, Clinical Cancer Research, vol.18, issue.8, pp.2336-2379, 2012.
DOI : 10.1158/1078-0432.CCR-11-2825

S. Li, K. Schmitz, P. Jeffrey, J. Wiltzius, P. Kussie et al., Structural basis for inhibition of the epidermal growth factor receptor by cetuximab, Cancer Cell, vol.7, issue.4, pp.301-312, 2005.
DOI : 10.1016/j.ccr.2005.03.003

J. Arnoletti, D. Buchsbaum, and Z. Huang, Mechanisms of resistance to Erbitux (anti?epidermal growth factor receptor) combination therapy in pancreatic adenocarcinoma cells, Journal of Gastrointestinal Surgery, vol.8, issue.8, pp.960-969, 2004.
DOI : 10.1016/j.gassur.2004.09.021

S. Bouali, Transfert des gènes p53 et pten par vectorisation non virale : effet proapoptotique et potentialisation de la réponse cellulaire au cetuximab, pp.1-195, 2008.

A. Poli, T. Michel, M. Thérésine, E. Andrès, F. Hentges et al., CD56 bright natural killer (NK) cells : an important NK cell subset New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) Radiation-induced proliferation of the human A431 squamous carcinoma cells is dependent on EGFR tyrosine phosphorylation, Immunology. Eur J Cancer. Oncogene, vol.126, issue.52, pp.458-465, 1997.

S. Huang, J. Bock, and P. Harari, Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cells carcinomas of the head and neck, Cancer Res, vol.59, issue.54, pp.1935-1975, 1999.

K. Dittmann, Radiation-induced Epidermal Growth Factor Receptor Nuclear Import Is Linked to Activation of DNA-dependent Protein Kinase, Journal of Biological Chemistry, vol.280, issue.35, pp.31182-31191, 2005.
DOI : 10.1074/jbc.M506591200

J. Bonner, Radiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and Neck, New England Journal of Medicine, vol.354, issue.6, pp.567-578, 2006.
DOI : 10.1056/NEJMoa053422

J. Bonner, Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival, The Lancet Oncology, vol.11, issue.1, pp.21-29, 2010.
DOI : 10.1016/S1470-2045(09)70311-0

D. Pfister, Y. Su, and D. Kraus, Concurrent Cetuximab, Cisplatin, and Concomitant Boost Radiotherapy for Locoregionally Advanced, Squamous Cell Head and Neck Cancer: A Pilot Phase II Study of a New Combined-Modality Paradigm, Journal of Clinical Oncology, vol.24, issue.7, pp.1072-1080, 2006.
DOI : 10.1200/JCO.2004.00.1792

M. Posner, D. Hershock, and C. Blajman, Cisplatin et fluorouracil alone or with docetaxel in head and neck cancer Cisplatine, fluorouracil and dicetaxel in unresectable head and neck cancer Antiepidermal growth factor receptor antibodies augment cytotoxicity of chemotherapeutic agents on squamous cell carcinoma cell lines Antitumor effect of anti-epidermal growth factor receptor monoclonal antibodies plus cis-diamminedichloroplatinium on well established A431 cell xenografts, N Engl J Med. N Engl J Med. Otolaryngol Head Neck Surg. Cancer Res, vol.357, issue.63, pp.1705-1720, 1993.

J. Bourhis, F. Rivera, and R. Mesia, Phase I/II study of cetuximab in combination with cisplatine or carboplatine and fluorouracil in patients with recurrent or metastatic squamous cell carcinoma of the head and neck Epidermal growth factor receptortargeted therapy with C225 and cisplatine in patients with head and neck cancer Eastern Cooperative Oncology Group. Phase III randomized trial of cisplatine plus placebo compared with cisplatine plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study, al. Platinum-based chemotherapy plus cetuximab in head and neck cancer, pp.286-72, 2001.

J. Baselga, J. Trigo, and J. Bouhis, Phase II Multicenter Study of the Antiepidermal Growth Factor Receptor Monoclonal Antibody Cetuximab in Combination With Platinum-Based Chemotherapy in Patients With Platinum-Refractory Metastatic and/or Recurrent Squamous Cell Carcinoma of the Head and Neck, Journal of Clinical Oncology, vol.23, issue.24, pp.5568-77, 2005.
DOI : 10.1200/JCO.2005.07.119

R. Herbst, M. Arquette, and D. Shin, Phase II Multicenter Study of the Epidermal Growth Factor Receptor Antibody Cetuximab and Cisplatin for Recurrent and Refractory Squamous Cell Carcinoma of the Head and Neck, Journal of Clinical Oncology, vol.23, issue.24, pp.5578-87, 2005.
DOI : 10.1200/JCO.2005.07.120

J. Anderson, J. Irish, C. Mclachlin, and N. By, H-ras Oncogene Mutation and Human Papillomavirus Infection in Oral Carcinomas, Archives of Otolaryngology - Head and Neck Surgery, vol.120, issue.7, pp.755-60, 1994.
DOI : 10.1001/archotol.1994.01880310059011

K. Okami, Analysis of PTEN/MMAC1 alterations in aerodigestive tract tumors, Cancer Res, vol.58, issue.82, pp.509-520, 1998.

G. Su, PIK3CA mutations in head and neck squamous cell carcinoma, Clin Cancer Res, vol.12, pp.1441-1447, 2006.

J. Pedrero, D. Carracedo, C. Pinto, A. Zapatero, J. Rodrigo et al., Frequent genetic and biochemical alterations of the PI 3-K/AKT/PTEN pathway in head and neck squamous cell carcinoma, International Journal of Cancer, vol.6, issue.2, pp.242-250, 2005.
DOI : 10.1002/ijc.20711

U. Stahl, Genomic gain of PIK3CA and increased expression of p110alpha are associated with progression of dysplasia into invasive squamous cell carcinoma, J Pathol, vol.198, issue.85, pp.335-377, 2002.

A. Psyrri, Z. Yu, and P. Weinberger, Quantitative Determination of Nuclear and Cytoplasmic Epidermal Growth Factor Receptor Expression in Oropharyngeal Squamous Cell Cancer by Using Automated Quantitative Analysis, Clinical Cancer Research, vol.11, issue.16, pp.5856-62, 2005.
DOI : 10.1158/1078-0432.CCR-05-0420

S. Wang and M. Hung, Nuclear Translocation of the Epidermal Growth Factor Receptor Family Membrane Tyrosine Kinase Receptors, Clinical Cancer Research, vol.15, issue.21, pp.6484-6493, 2009.
DOI : 10.1158/1078-0432.CCR-08-2813

J. Boyle, The incidence of p53 mutations increases with progression of head and neck cancer, Cancer Res, vol.53, issue.88, pp.4477-80, 1993.

K. Freier, F. Bosch, C. Flechtenmacher, F. Devens, A. Benner et al., Distinct site-specific oncoprotein overexpression in head and neck squamous cell carcinoma: a tissue microarray analysis, 89. Reed AL et al. High frequency of p16 (CDKN2/MTS-1/INK4A) inactivation in head and neck squamous cell carcinoma, pp.3971-3978, 1996.

G. Yoo, H. Xu, J. Brennan, W. Westra, R. Hruban et al., Infrequent inactivation of the retinoblastoma gene despite frequent loss of chromosome 13q in head and neck squamous cell carcinoma Vascular endothelial growth factor expression in head and neck squamous cell carcinoma, Cancer Res. Am J Surg, vol.54, issue.174, pp.4603-4609, 1994.

P. Perlmann, H. Perlmann, and H. Wigzell, Lymphocyte Mediated Cytotoxicity in Vitro. Induction and Inhibition by Humoral Antibody and Nature of Effector Cells, Immunological Reviews, vol.1, issue.1, pp.91-114, 1972.
DOI : 10.1016/S0140-6736(71)92741-3

J. Titus, P. Perez, A. Kaubisch, M. Garrido, and D. Segal, Human K/natural killer cells targeted with hetero-cross-linked antibodies specifically lyse tumor cells in vitro and prevent tumor growth in vivo Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets, J Immunol. Nat Med, vol.139, issue.6, pp.3153-3158, 1987.

J. Kurai, H. Chikumi, and K. Hashimoto, Antibody-Dependent Cellular Cytotoxicity Mediated by Cetuximab against Lung Cancer Cell Lines, Clinical Cancer Research, vol.13, issue.5, pp.1552-61, 2007.
DOI : 10.1158/1078-0432.CCR-06-1726

W. Zhang, M. Gordon, and A. Schultheis, FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab Therapeutic potential of chimeric and murine anti-(epidermal growth factor receptor) antibodies in a metastasis model for human melanoma, J Clin Oncol. Cancer Immunol Immunother, vol.25, issue.37, pp.3712-3730, 1993.

W. Weng and R. Levy, Two Immunoglobulin G Fragment C Receptor Polymorphisms Independently Predict Response to Rituximab in Patients With Follicular Lymphoma, Journal of Clinical Oncology, vol.21, issue.21, pp.3940-3947, 2003.
DOI : 10.1200/JCO.2003.05.013

G. Cartron, L. Dacheux, and G. Salles, Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor Fcgamma RIIIa gene, Blood, vol.99, issue.3, pp.754-762, 2002.
DOI : 10.1182/blood.V99.3.754

P. Warmerdam, J. Van-de-winkel, E. Gosselin, and P. Capel, Molecular basis for a polymorphism of human Fc gamma receptor II (CD32), Journal of Experimental Medicine, vol.172, issue.1, pp.19-25, 1990.
DOI : 10.1084/jem.172.1.19

P. Warmerdam, J. Van-de-winkel, A. Vlug, N. Westerdaal, and P. Capel, A single amino acid in the second Ig-like domain of the human Fc gamma receptor II is critical for human IgG2 binding, J Immunol, vol.147, issue.102, pp.1338-1381, 1991.

H. Koene, M. Kleijer, J. Algra, D. Roos, V. Dem-borne et al., Fc gammaRIIIa-158V/F polymorphism influences the binding of IgG by natural killer cell Fc gammaRIIIa, independently of the Fc gammaRIIIa-48L/R/H phenotype High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R, Blood. J Biol Chem, vol.90, issue.104, pp.1109-1123, 1997.

T. Vance-ban-huizinga, K. Wardwell, and P. Guyre, Binding of monomeric human IgG defines an expression polymorphism of Fc gamma RIII on large granular lymphocyte/natural killer cells, J Immunol, vol.151, issue.105, pp.6429-6468, 1993.

E. Hatjiharissi, L. Xu, and D. Santos, Increased natural killer cell expression of CD16, augmented binding and ADCC activity to rituximab among individuals expressing the Fc{gamma}RIIIa-158 V Van sorge NM, Van der Pol WL, Van de Winkel JG. FcgammaR polymorphisms: Implications for function, disease susceptibility and immunotherapy, Blood. Tissue Antigens, vol.110, issue.107, pp.2561-2565, 2003.

S. Farag, I. Flinn, R. Modali, T. Lehman, D. Young et al., Fc gamma RIIa and Fc gamma RIIa polymorphisms do not predict response to rituximab in B-cell chronic lymphocytic leukemia Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of Trastuzumab-based therapy in patients with HER- 2/neu-positive metastatic breast cancer, Blood. J Clin Oncol, vol.103, issue.109, pp.1472-1476, 2004.

F. Bibeau, E. Lopez-crapez, D. Fiore, and F. , Impact of Fc{gamma}RIIa- Fc{gamma}RIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus Irinotecan Role of polymorphic Fc gamma receptor IIIa and EGFR expression level in cetuximab mediated, NK cell dependent in vitro cytotoxicity of head and neck squamous cell carcinoma cells, J Clin Oncol. Cancer Immunol Immunother, vol.27, issue.111, pp.1122-1131, 2009.

R. Taylor, S. Chan, and A. Wood, FcgammaRIIIa polymorphisms and cetximab induced cytotoxicity in squamous cell carcinoma of the head and neck 112. Fr.wikipedia.org/wiki/reaction_en_chaîne_par_polymérase Evaluation de la fonction des cellules natural killer chez les patients présentant un carcinome épidermoïde des voies aérodigestives supérieures en situation palliative, devant recevoir du cétuximab : une étude préliminaire. Annales Française d'Oto-Rhino-Laryngologie et de Pathologie Cervico- Faciale, Cancer Immunol Immunother. Bon-Mardion N, vol.58130, issue.113, pp.997-1006, 2009.

F. Robert, M. Ezekiel, S. Spencer, R. Meredith, and J. Bonner, Phase I Study of Anti???Epidermal Growth Factor Receptor Antibody Cetuximab in Combination With Radiation Therapy in Patients With Advanced Head and Neck Cancer, Journal of Clinical Oncology, vol.19, issue.13, pp.3234-3277, 2001.
DOI : 10.1200/JCO.2001.19.13.3234

D. Gancz and Z. Fishelson, Cancer resistance to complement-dependent cytotoxicity (CDC): Problem-oriented research and development, Molecular Immunology, vol.46, issue.14, pp.2794-800, 2009.
DOI : 10.1016/j.molimm.2009.05.009

D. Liu and Z. Niu, The structure, genetic polymorphisms, expression and biological functions of complement receptor type 1 (CR1/CD35), Immunopharmacology and Immunotoxicology, vol.95, issue.9, pp.524-559, 2009.
DOI : 10.1016/0952-7915(91)90081-B

M. Dechant, W. Weisner, and S. Berger, Complement-dependent tumor cell lysis triggered by combinations of epidermal groth factor receptor antibodies al. Dual mode of action of a human anti-epidermal growth factor receptor monoclonal antibody for cancer therapy, Cancer Res. Bleeker WK J Immunol, vol.68, issue.120, pp.4998-5003, 2004.

H. Kimura, K. Sakai, T. Arao, T. Shimoyama, T. Tamura et al., Antibody-dependent cellular cytotoxicity of cetuximab against tumor cells with wild-type or mutant epidermal growth factor receptor, Cancer Science, vol.139, issue.8, pp.1275-80, 2007.
DOI : 10.1074/jbc.M210665200

J. Sampson, L. Crotty, and S. Lee, Unarmed, tumor-specific monoclonal antibody effectively treats brain tumors, Proceedings of the National Academy of Sciences, vol.97, issue.13, pp.7503-7511, 2000.
DOI : 10.1073/pnas.130166597

F. Gonzàlez, J. Vargas, and C. Lòpez-cortijo, Prognostic Significance of Natural Killer Cell Activity in Patients With Laryngeal Carcinoma, Archives of Otolaryngology???Head & Neck Surgery, vol.124, issue.8, pp.852-858, 1998.
DOI : 10.1001/archotol.124.8.852

D. Hanahan, R. Weinberg, A. Duray, S. Demoulin, P. Hubert et al., Hallmarks of cancer: the next generation Immune suppression in head and nack cancers: a review, Cell. Clin Dev Immunol, vol.144, issue.124, pp.646-74, 2010.

P. Beum, D. Mack, A. Pawluczkowycz, M. Lindorfer, and R. Taylor, Binding of Rituximab, Trastuzumab, Cetuximab, or mAb T101 to Cancer Cells Promotes Trogocytosis Mediated by THP-1 Cells and Monocytes, Thèse de médecine ? Université Bordeaux 2 Victor Segalen, pp.8120-8152, 2008.
DOI : 10.4049/jimmunol.181.11.8120

J. Vermorken, J. Trigo, and R. Hitt, Epidermal growth factor receptor variant III mediates head and neck cancer cell invasion via STAT3 activation Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy, Oncogene. J Clin Oncol, vol.29, issue.129, pp.5135-5180, 2007.

C. Chung, B. Mirakhur, E. Chan, Q. Le, and J. Berlin, Cetuximab-Induced Anaphylaxis and IgE Specific for Galactose-??-1,3-Galactose, New England Journal of Medicine, vol.358, issue.11, pp.1109-1126, 2008.
DOI : 10.1056/NEJMoa074943

W. Yang, G. Wu, R. Barth, M. Swindall, and A. Bandyopadhyaya, Molecular Targeting and Treatment of Composite EGFR and EGFRvIII-Positive Gliomas Using Boronated Monoclonal Antibodies, Clinical Cancer Research, vol.14, issue.3, pp.883-91, 2008.
DOI : 10.1158/1078-0432.CCR-07-1968

H. Jiang, H. Wang, Z. Tan, S. Hu, and H. Wang, Growth Suppression of Human Hepatocellular Carcinoma Xenografts by a Monoclonal Antibody CH12 Directed to Epidermal Growth Factor Receptor Variant III, Journal of Biological Chemistry, vol.286, issue.7, pp.5913-5933, 2011.
DOI : 10.1074/jbc.M110.192252